Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Merkel Cell × Etoposide × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 136 Lymphoma, Large B-Cell, Diffuse 101 Lymphoma, Non-Hodgkin 97 Precursor Cell Lymphoblastic Leukemia-Lymphoma 95 Leukemia 78 Hodgkin Disease 77 Small Cell Lung Carcinoma 68 Leukemia, Myeloid, Acute 66 Burkitt Lymphoma 62 Lymphoma, Follicular 59 Lymphoma, Mantle-Cell 55 Lung Neoplasms 53 Lymphoma, Large-Cell, Immunoblastic 49 Leukemia, Lymphocytic, Chronic, B-Cell 45 Multiple Myeloma 35 Recurrence 34 Lymphoma, B-Cell, Marginal Zone 33 Neuroblastoma 27 Congenital Abnormalities 25 Carcinoma, Non-Small-Cell Lung 24 Myelodysplastic Syndromes 23 Brain Neoplasms 20 Sarcoma 19 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19 Lymphoma, Large-Cell, Anaplastic 19 Lymphoma, B-Cell 19 Ovarian Neoplasms 18 Lymphoma, T-Cell, Peripheral 17 Lymphoma, Extranodal NK-T-Cell 17 Dendritic Cell Sarcoma, Interdigitating 17

Interventions

pembrolizumab 12 avelumab 8 Radiotherapy 8 Nivolumab 7 cemiplimab 4 Radiation 4 Ipilimumab 4 poly ICLC 3 atezolizumab 3 Cyclophosphamide 3 talimogene laherparepvec 2 lutetium Lu 177 dotatate 2 fludarabine phosphate 2 fludarabine 2 durvalumab 2 aldesleukin 2 Specimen Handling 2 Magnetic Resonance Spectroscopy 2 Interferon-beta 2 Immunoglobulin G 2 Immune Checkpoint Inhibitors 2 Biopsy 2 veliparib 1 vatalanib 1 tremelimumab 1 tocilizumab 1 temsirolimus 1 sargramostim 1 sapanisertib 1 relatlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06086288 2023-10-17

PANDORA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡